NCT06375993 - A Phase 1 Study of ADI-001 in Autoimmune Disease | Biotech Hunter

Enrollment

180

Participants

Timeline

Start Date

November 10, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions

Lupus NephritisAutoimmune DiseasesSystemic Sclerosis (SSc)Systemic Lupus Erythematosus (SLE)ANCA-Associated Vasculitis (AAV)Idiopathic Inflammatory MyopathiesStiff Person Syndrome

Interventions

DRUG

ADI-001

Anti-CD20 CAR-T

DRUG

Fludarabine

Chemotherapy for Lymphodepletion

DRUG

Cyclophosphamide

Chemotherapy for Lymphodepletion

Trial Locations (2)

14263

RECRUITING

Roswell Park Comprehensive Cancer Center, Buffalo

94065

RECRUITING

Adicet Clinical Trials, Redwood City